Proton pump inhibitors may reduce tumour resistance

Bibliography

• GOTTESMAN MM, PASTAN I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. (1993) 62:385–427.
   PubMed Web of Science ®Google Scholar
• LUCIANI F, MOLINARI A. LOZUPONE F et al.: P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood (2002) 99:641–648.
   Google Scholar
• •First description of a possible link between the ERNI proteins and multi-drug resistance.
   Google Scholar
• IVETIC A, RIDLEY AJ: Ezrin/radixin/ moesin proteins and Rho GTPase signalling in leucocytes. Immunology (2004) 112:165–176.
   PubMed Web of Science ®Google Scholar
• RAGHUNAND N, HEX, VAN SLUIS R et al.: Enhancement of chemotherapy by manipulation of tumor pH. Br. J. Cancer (1999) 80:1005–1011.
   Google Scholar
• ••First and elegant in vivo study showingthat bicarbonate-induced increase of tumour pH improved therapeutic efficacy of doxorubicin.
   Google Scholar
• TANNOCK IF, ROTIN D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. (1989) 49:4373–4384.
   PubMed Web of Science ®Google Scholar
• IZUMI H, TORIGOE T, ISHIGUCHU Het al.: Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev. (2003) 29:541–549.
   Google Scholar
• MAHONEY BP, RAGHUNAND N, BAGGET B, GILLIES RJ: Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. PharmacoL (2003) 66:1207–1218.
   Google Scholar
• SIMON S, ROY D, SCHINDLER M: Intracellular pH and the control of multidrug resistance. Proc. NatL Acad. Sci. USA (1994) 91:1128–1132.
   PubMed Web of Science ®Google Scholar
• NEWELL K, WOOD P, STRATFORD I, TANNOCK I: Effects of agents which inhibit the regulation of intracellular pH on murine solid tumors. Br. J. Cancer (1992) 66:311–317.
   PubMedGoogle Scholar
• RAGHUNAND N, GILLIES RJ: pH and drug resistance in tumors. Drug Resist. Update (2000) 3:39–47.
   PubMed Web of Science ®Google Scholar
• OHTSUBO T, IGAWA H, SAITO T et ell.:Acidic environment modifies heat- or radiation-induced apoptosis in human maxillary cancer cells. Int. J. Radiat. OncoL Biol. Phys. (2001) 49:1391–1398.
   Google Scholar
• RAGHUNAND N, MARTINEZ-ZAGUILAN R, WRIGHT SH, GILLIES RJ: pH and drug resistance. II. Turnover of acidic vesicles and resistance to wealdy basic chemotherapeutic drugs. Biochem. PharmacoL (1999) 57:1047–1058.
   Google Scholar
• •Paper describing the turnover of acidic vesicles as an important factor in chemoresistance.
   Google Scholar
• SCHINDLER M, GRABSKI S, HOFF E, SIMON SM: Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry (1996) 35:2811–2817.
   PubMed Web of Science ®Google Scholar
• HURWITZ SJ, TERASHIMA M, MIZUNUMA N, SLAPAK CA: Vesicular anthracycline accumulation in doxorubicin-selected U937 cells: participation of lysosomes. Blood (1997) 89:3745–3754.
   PubMed Web of Science ®Google Scholar
• ALTAN N, CHEN Y, SCHINDLER M, SANFORD SM: Defective acidification in human breast tumor cells and implications for chemotherapy. J. Exp. Med. (1998) 187:1583–1598.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of the causal relationship between acidification of intracellular organelles and drug resistance.
   Google Scholar
• LARSEN AK, ESCARGUEIL AE, SKLADANOWSKI A: Resistance mechanisms associated with altered intracellular distribution of anticancer agents. PharmacoL Ther. (2000) 85:217–229.
   PubMed Web of Science ®Google Scholar
• LUCIANI F, SPADA M, DE MILITO A et al.: Effect of proton pump inhibitor pre-treatment on resistance of solid tumors to cytotoxic drugs. J. NatL Cancer Inst. (2004) 96:1702–1713.
   Google Scholar
• ••Evidence that PPIs reverse resistance tocytotoxic drugs in vitro and in vivo likely through modifications of tumour pH.
   Google Scholar
• RAGHUNAND N, MAHONEY BP, VAN SLUIS R, BAGGETT B, GILLIES RJ: Acute metabolic alkalosis enhances response of C3H muose mammary tumors to weak base mitoxantrone. Neoplasia (2001) 3:227–235.
   PubMed Web of Science ®Google Scholar
• RAGHUNAND N, MAHONEY BP, GILLIES RJ: Tumor acidity, ion trapping and chemotherapeutics II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic therapeutic agents. Biochem. PharmacoL (2003) 66:1219–1229.
   Google Scholar
• DIETEL M, ARPS H, LAGE H, NIENDORF A: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. (1990) 50:6100–6106.
   PubMed Web of Science ®Google Scholar
• BOBICHON H, COLIN M, DEPIERREUX C, LIAUTAUD-ROGER F, JARDILLIER JC: Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J. Exp.Ther. OncoL (1996) 1:49–61.
   PubMedGoogle Scholar
• CLEARY I, DOHERTY G, MORAN E, CLYNES M: The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. PharmacoL (1997) 53:1493–1502.
   PubMed Web of Science ®Google Scholar
• BOUR-DILL C, GRAMAIN MP, MERLIN JL, MARCHAL S, GUILLEMIN F: Determination of intracellular organdies implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry (2000) 39:16–25.
   PubMedGoogle Scholar
• OUAR Z, LACAVE R, BENS M, VANDEWALLE A: Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug resistant cells. Cell Biol. Toxicol. (1999)15:91–100.
   PubMed Web of Science ®Google Scholar
• LUGINI L, LOZUPONE F, MATARRESE P et al.: Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab. Invest. (2003) 83:1555–1567.
   PubMed Web of Science ®Google Scholar
• •Paper suggesting that metastatic behaviour of human tumours may be correlated to the acidity of intracellular vesicles.
   Google Scholar
• ANDREOLA G, RIVOLTINI L, CASTELLI Get al.: Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. (2002) 195:1303–1316.
   Google Scholar
• •Evidence that tumours may use vesicular trafficking as a mean to evade immune control.
   Google Scholar
• TAYLOR DD, TAYLOR CG: Tumor-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer (2005) 1–7 (Epub ahead of print).
   Google Scholar
• NISHI T, FORGAC M: The vacuolar (FP)-ATPases - Nature's most versatile proton pumps. Nat. Rev. Mol. Cell Biol. (2002) 3:94–103.
   PubMed Web of Science ®Google Scholar
• •A complete and well-written review on vacuolar H*-ATPases.
   Google Scholar
• VAANANEN HK, KARHUKORPI EK, SUNQUIST K et al.: Evidence of the presence of H*-ATPase types in the ruffled borders of osteoclasts. J. Cell Biol. (1990) 111:1305–1311.
   PubMed Web of Science ®Google Scholar
• •First evidence of the involvement of vacuolar H*-ATPases in drug resistance in tumours.
   Google Scholar
• MARQUARDT D, CENTER MS: Involvement of vacuolar H+-adenosine triphosphatase activity in multidrug resistance in HL60 cells. J. Natl Cancer Inst. (1991) 83:1098–1102.
   PubMedGoogle Scholar
• MARTINEZ-ZAGUILAN R, LYNCH RM, MARTINEZ GM, GILLIES RJ: Vacuolar-type FPATPases are functionally expressed in the plasma membranes of human tumor cells. Am. J. PhysioL (1993) 265:C1015–C1029.
   Google Scholar
• MURAKAMI T, SHIBUYA I, ISE T et ell.:Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int. J. Cancer (2001) 93:869–874.
   Google Scholar
• OUAR Z, BENS M, VIGNES C et al.: Inhibitors of vacuolar H*-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J. (2003) 370:185–193.
   PubMedGoogle Scholar
• •Evidence that inhibitors of vacuolar FP-ATPases may reverse drug resistance through lysosomal-mediated mechanisms.
   Google Scholar
• LARSSON H, MATTSON H, SUNDELL G, CARLSSON E: Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. Scand. J. Gastroenterol (1985) 20\(Suppl. 108):23–35.
   Google Scholar
• WALLMARK B, LARSSON H, HUMBLE L: The relationship between gastric acid secretion and gastric FP,K*-ATPase activity. Biol. Chem. (1985) 260:13681–13684.
   Google Scholar
• WALLMARK B, LORENTZON P, LARSSON H: The mechanism of action of omeprazole - a survey of its inhibitory action in vivo. Scand. J. Gastroenterol (1985) 20\(Suppl. 108):37–51.
   Google Scholar
• PUSCAS I, COLTAU M, BAICAN M, DOMUTA G: Omeprazole has a dual mechanism of action: it inhibits both H*K*ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). J. Pharmacol. Exp. Ther. (1999) 290:530–534.
   PubMed Web of Science ®Google Scholar
• HORN J: The proton-pump inhibitors: similarities and differences. Clin. Ther. (2000) 22:266–280.
   PubMed Web of Science ®Google Scholar
• MIZUNASHI K, FURUKAWA Y, KATANO K, ABE K: Effect of omeprazole, an inhibitor of H*,K(*)-ATPase, on bone resorption in humans. Cala."' Tissue Int. (1993) 53:21–25.
   PubMed Web of Science ®Google Scholar
• GRABER ML, DEVINE P: Omeprazole and SCH 28080 inhibit acid secretion by the turtle urinary bladder. Ren. PhysioL Biochem. (1993) 16:257–267.
   PubMedGoogle Scholar
• SABOLIC I, BROWN D, VERBAVATZ JM, KLEINMAN J: H(*)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am. J. Physiol. (1994) 266: F868–F877.
   Google Scholar
• BIS WAS K, BANDYOPADHYAY U, CHATTOPADHYAY I, VARADARAJ A, ALI E, BANERJEE RK: A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J. Biol. Chem. (2003) 278:10993–11001.
   PubMedGoogle Scholar
• AGASTYA G, WEST BC, CALLAHAN JM: Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. (2000) 22:357–372.
   PubMed Web of Science ®Google Scholar
• CIANFRIGLIA M, CENCIARELLI C, TOMBESI M et al.: Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multidrug-resistant variants of GEM cells. Int. J. Cancer (1990) 45:95–103.
   PubMedGoogle Scholar